Stem Cells International / 2015 / Article / Fig 4

Research Article

Multiple Myeloma Patients at Various Cytogenetic Risks Benefit Differently from Autologous Stem Cell Transplantation as a Consolidation Therapy

Figure 4

Comparison of OS in the patients of ASCT group and non-ASCT group in the high-risk subgroup. The median OS was prolonged 51.5 months in ASCT group (85.5 versus 34 months, ).